| Crohn Disease
Remicade vs Tysabri
Side-by-side clinical, coverage, and cost comparison for crohn disease.Deep comparison between: Remicade vs Tysabri with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTysabri has a higher rate of injection site reactions vs Remicade based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tysabri but not Remicade, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Remicade
Tysabri
At A Glance
IV infusion
Every 8 weeks
TNF-alpha inhibitor
IV infusion
Every 4 weeks
alpha4-integrin antagonist
Indications
- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Psoriasis vulgaris
- Multiple Sclerosis
- Crohn Disease
Dosing
Crohn Disease, Ulcerative Colitis 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks (adults and pediatric patients >= 6 years).
Rheumatoid Arthritis 3 mg/kg IV induction at 0, 2, and 6 weeks, then 3 mg/kg every 8 weeks in combination with methotrexate; dose may be increased up to 10 mg/kg every 8 weeks or every 4 weeks for incomplete responders.
Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks.
Multiple Sclerosis 300 mg IV infusion over one hour every four weeks.
Crohn Disease 300 mg IV infusion over one hour every four weeks; discontinue if no therapeutic benefit by 12 weeks of induction therapy or if concomitant corticosteroids cannot be tapered within six months of starting therapy.
Contraindications
- Doses >5 mg/kg in patients with moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab, any inactive ingredient of REMICADE, or any murine proteins (including anaphylaxis, hypotension, and serum sickness)
- Progressive multifocal leukoencephalopathy (PML), current or historical
- Previous hypersensitivity reaction to TYSABRI, ranging from urticaria to anaphylaxis
Adverse Reactions
Most common (>10%) Infections (upper respiratory tract infection, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain.
Serious Pneumonia, cellulitis, abscess, sepsis, bacterial infection, hepatotoxicity, acute liver failure, malignancies (including lymphoma), pancytopenia, thrombocytopenia, leukopenia.
Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, peripheral demyelinating disorders, anaphylactic shock, cerebrovascular accidents, myocardial ischemia/infarction.
Most common (>=10%) Headache, fatigue (MS and CD); arthralgia, urinary tract infection, lower respiratory tract infection, gastroenteritis, vaginitis, depression, pain in extremity, abdominal discomfort, diarrhea, rash (MS); upper respiratory tract infection, nausea (CD).
Serious Progressive multifocal leukoencephalopathy (PML), herpes infections, hepatotoxicity, hypersensitivity and antibody formation, immunosuppression and infections, hematological abnormalities.
Postmarketing Hemolytic anemia, thrombocytopenia (including immune thrombocytopenic purpura).
Pharmacology
TNF-alpha antagonist; infliximab is a chimeric IgG1 monoclonal antibody that neutralizes the biological activity of TNF-alpha by binding with high affinity to both soluble and transmembrane forms of TNF-alpha and inhibiting its binding to receptors, thereby reducing inflammation in RA, CD, UC, AS, PsA, and Ps.
Alpha4-integrin antagonist; recombinant humanized IgG4 monoclonal antibody that binds to the alpha4-subunit of alpha4beta1 and alpha4beta7 integrins on leukocytes, blocking their adhesion to VCAM-1 and MAdCAM-1 and inhibiting transmigration into inflamed parenchymal tissue in multiple sclerosis and Crohn's disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Remicade
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (0/12)
Tysabri
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Remicade
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tysabri
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Remicade
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Tysabri
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Remicade.
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RemicadeView full Remicade profile
TysabriView full Tysabri profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.